Search Results - "Chen, T.‐L."

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) by Boku, N., Ryu, M.-H., Kato, K., Chung, H.C., Minashi, K., Lee, K.-W., Cho, H., Kang, W.K., Komatsu, Y., Tsuda, M., Yamaguchi, K., Hara, H., Fumita, S., Azuma, M., Chen, L.-T., Kang, Y.-K.

“…Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after…”
Get full text

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS by Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T.W., Ismail, F., Tan, I.B., Yeh, K.-H., Grothey, A., Zhang, S., Ahn, J.B., Mastura, M.Y., Chong, D., Chen, L.-T., Kopetz, S., Eguchi-Nakajima, T., Ebi, H., Ohtsu, A., Cervantes, A., Muro, K., Tabernero, J., Minami, H., Ciardiello, F., Douillard, J.-Y.

“…The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal…”
Get full text

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma by Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

“…Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting…”
Get full text

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions by Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M.J., Yeh, K.-H., Baba, E., Naito, Y., Calvo, F., Saxena, A., Chen, L.-T., Takeda, M., Cervantes, A., Taniguchi, H., Yoshida, K., Kodera, Y., Kitagawa, Y., Tabernero, J., Burris, H., Douillard, J.-Y.

“…A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Kato, K., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Nakajima, T.E., Shitara, K., Kawakami, H., Narita, Y., Yoshino, T., Van Cutsem, E., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of…”
Get full text

Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host by Sonnenburg, Justin L, Chen, Christina T L, Gordon, Jeffrey I

“…Probiotics are deliberately ingested preparations of live bacterial species that confer health benefits on the host. Many of these species are associated with…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO by Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai, D., Vogel, A., Cervantes, A., Lu, S.-N., Yen, C.-J., Huang, Y.-H., Chen, S.-C., Hsu, C., Shen, Y.-C., Tabernero, J., Yen, Y., Hsu, C.-H., Yoshino, T., Douillard, J.-Y.

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of…”
Get full text

Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer by Chang, Y-W, Tseng, C-F, Wang, M-Y, Chang, W-C, Lee, C-C, Chen, L-T, Hung, M-C, Su, J-L

“…Heat-shock protein 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an important role in cancer progression, including promoting drug…”
Get full text

IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma by Liu, Y., Li, F., Yang, Y. T., Xu, X. D., Chen, J. S., Chen, T. L., Chen, H. J., Zhu, Y. B., Lin, J. Y., Li, Y., Xie, X. M., Sun, X. L., Ke, Y. Q.

“…Vasculogenic mimicry (VM) refers to the fluid-conducting channels formed by aggressive tumor cells rather than endothelial cells (EC) with elevated expression…”
Get full text

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer by Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T

“…Background: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug…”
Get full text

ARGO-YBJ OBSERVATION OF THE LARGE-SCALE COSMIC RAY ANISOTROPY DURING THE SOLAR MINIMUM BETWEEN CYCLES 23 AND 24 by Bartoli, B., Bernardini, P., Bi, X. J., Cao, Z., Catalanotti, S., Chen, S. Z., Chen, T. L., Cui, S. W., Dai, B. Z., D'Amone, A., Danzengluobu, Mitri, I. De, Piazzoli, B. D'Ettorre, Girolamo, T. Di, Sciascio, G. Di, Feng, C. F., Feng, Zhaoyang, Feng, Zhenyong, Gao, W., Gou, Q. B., Guo, Y. Q., He, H. H., Hu, Haibing, Hu, Hongbo, Iacovacci, M., Iuppa, R., Jia, H. Y., Labaciren, Li, H. J., Liu, C., Liu, J., Liu, M. Y., Lu, H., Ma, L. L., Ma, X. H., Mancarella, G., Mari, S. M., Marsella, G., Mastroianni, S., Montini, P., Ning, C. C., Perrone, L., Pistilli, P., Salvini, P., Santonico, R., Shen, P. R., Sheng, X. D., Shi, F., Surdo, A., Tan, Y. H., Vallania, P., Vernetto, S., Vigorito, C., Wang, H., Wu, C. Y., Wu, H. R., Xue, L., Yang, Q. Y., Yang, X. C., Yao, Z. G., Yuan, A. F., Zha, M., Zhang, H. M., Zhang, L., Zhang, X. Y., Zhang, Y., Zhao, J., Zhaxiciren, Zhaxisangzhu, Zhou, X. X., Zhu, F. R., Zhu, Q. Q.

“…ABSTRACT This paper reports on the measurement of the large-scale anisotropy in the distribution of cosmic-ray arrival directions using the data collected by…”
Get full text

Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii by Chen, T.-L., Sin, L.-K., Wu, R.C.-C., Shaio, M.-F., Huang, L.-Y., Fung, C.-P., Lee, C.-M., Cho, W.-L.

“…Acinetobacter baumannii has emerged as a serious cause of nosocomial infections. Rapid identification of this pathogen is required so that appropriate therapy…”
Get full text

Risk and outcomes of fracture in peripheral arterial disease patients: two nationwide cohort studies by Liu, F.-L., Lin, C.-S., Yeh, C.-C., Shih, C.-C., Cherng, Y.-G., Wu, C.-H., Chen, T.-L., Liao, C.-C.

“…Summary Using national insurance claims data of Taiwan, we found that patients with peripheral arterial disease (PAD) had increased risk of fracture during the…”
Get full text

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma by Roy, A.C., Park, S.R., Cunningham, D., Kang, Y.K., Chao, Y., Chen, L.T., Rees, C., Lim, H.Y., Tabernero, J., Ramos, F.J., Kujundzic, M., Cardic, M.B., Yeh, C.G., de Gramont, A.

“…PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study evaluated the efficacy and safety of single…”
Get full text

Effects of red yeast rice prescription (LipoCol Forte) on adverse outcomes of surgery by Chen, T -L, Yeh, C -C, Lin, C -S, Shih, C -C, Liao, C -C

“…Abstract Background The influence of red yeast rice (RYR) on perioperative outcome remains unknown. Aim We aimed to compare the complications and mortality…”
Get full text

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma by Shiah, H.‐S., Chen, C.‐Y., Dai, C.‐Y., Hsiao, C.‐F., Lin, Y.‐J., Su, W.‐C., Chang, J.‐Y., Whang‐Peng, J., Lin, P.‐W., Huang, J.‐D., Chen, L.‐T.

“…Summary Background Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). Aim To determine the…”
Get full text

Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study by Kuo, S.-C., Lee, Y.-T., Yang, S.-P., Chen, C.-P., Chen, T.-L., Hsieh, S.-L., Siu, L.-K., Fung, C.-P.

“…Repeated isolation of multidrug-resistant Acinetobacter baumannii (MDRAB) from respiratory secretions poses a great challenge for infection control. We…”
Get full text

miR-520h is crucial for DAPK2 regulation and breast cancer progression by Su, C-M, Wang, M-Y, Hong, C-C, Chen, H-A, Su, Y-H, Wu, C-H, Huang, M-T, Chang, Y-W, Jiang, S-S, Sung, S-Y, Chang, J-Y, Chen, L-T, Chen, P-S, Su, J-L

“…MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3’untranslated region of specific target mRNAs. Although the…”
Get full text

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients by Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., Chen, L. T.

“…Purpose To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan,…”
Get full text